Development of iPSC-based CTL therapy for HTLV-1 infection

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19590
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Hematology
• Research Institution: National Institute of Infectious Diseases
• Principal Investigator: TEZUKA Kenta 国立感染症研究所, 血液・安全性研究部, 研究員 (10754533)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: HTLV-1 感染症 / 発症高リスク群 / Tax特異的CTL / iPS細胞

Outline of Final Research Achievements

Toward achievement of the HTLV-1 prophylaxis and cure strategy, I assessed the potential for using induced pluripotent stem (iPS) cell technology for development of a new immunotherapy. The frequency of Tax-specific CTLs was quite low, and its phenotypes showed senescent, less survival, and dysfunctional behaviors in a portion of chronic HTLV-1 carriers with high proviral load (4% > PVL). Patient-derived HTLV-1-specific regenerated CTL therapy could be a promising strategy to prevent or treat HTLV-1-associated diseases among these carriers.

Free Research Field

血液内科学